Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis. | Aplastic Anemia & MDS International Foundation

Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.

Journal Title: 
Crit Rev Oncol Hematol
Primary Author: 
Tang Y
Author(s): 
Tang Y, Miao M, Han S, Qi J, Wang H, Ruan C, Wu D, Han Y.
Original Publication Date: 
Tuesday, January 1, 2019
SF3B1 gene mutations are the most frequent mutations found in myelodysplastic syndromes (MDS), and the prognostic implication of these mutations remains controversial. We conducted a meta-analysis of studies assessing the prognostic impact and clinical feature of SF3B1 mutations in MDS patients. The overall hazard ratio for overall survival (OS) was 0.90 (95% confidence interval 0.60-1.35, P = 0.61) in MDS patients with SF3B1 mutations compared to those without. Lower leukemia-free survival was associated with SF3B1 mutations. Subgroup analyses showed that Asian cohorts and Illumina HiSeq 2000 methods were significantly associated with OS. Furthermore, SF3B1 mutations were significantly correlated with a lower level of blast cells and a high level of platelet counts and bone marrow ring sideroblasts. Thus, the current meta-analysis suggests that SF3B1 mutations have no significant impact on the OS of MDS patients, and the hematologic parameters of SF3B1 mutations identify a distinct subset of MDS patients with homogeneous features.
Bone Marrow Diseases: